The application for marketing authorization of trivalent influenza virus split vaccine has been accepted
October 8, 2025
Source: drugdu
88
People's Finance News reported on September 24 that Kangtai Biological(300601) announced on September 24 that the influenza vaccine developed by the companyThe application for marketing authorization of the viral split vaccine recently received an acceptance notice issued by the National Medical Products Administration.
The influenza virus split vaccine whose marketing authorization application was accepted this time is a trivalent influenza vaccine. Together with the quadrivalent influenza virus split vaccine that the company has applied for production registration, the quadrivalent influenza virus split vaccine (for people aged 6-35 months) that has been approved for clinical trials, the quadrivalent influenza virus split vaccine (MDCK cells) and the trivalent influenza virus split vaccine (MDCK cells), they constitute an influenza vaccine series covering all age groups.
https://finance.eastmoney.com/a/202509243522587919.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
